// App-Quantinova.ai

OA0120 : Extended daily dosing of AR101 for peanut allergy results in higher tolerated doses and continued immunomodulation

Researchers

Presenter

  • Blmchen K

Principal Investigators

  • Shreffler WG

  • Griffin NM

  • Zawadzki R

  • Matthews J

  • Ibez

  • Muraro A

  • Jones SM

  • Du Toit G

  • Hourihane JO

Medical Centers

  • University Hospital Frankfurt, Frankfurt, Germany

  • Massachusetts General Hospital, Boston, MA, United States

  • Aimmune Therapeutics, Brisbane, United States

  • Hospital Infantil Universitario Nino Jesus, Madrid, Spain

  • ARADyAL, Madrid, Spain

  • Food Allergy Referral Centre Veneto Region, Department of Woman and Child Health, Padua University Hospital, Padua, Italy

  • University of Arkansas for Medical Sciences and Arkansas Childrens Hospital, Little Rock, United States

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • University College Cork, Cork, Ireland

Locations

  • Germany

  • United States

  • Spain

  • Italy

  • United Kingdom

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Immunoglobulin E

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved